These observations, pertaining to the clinical management of PC, underlaid, for instance, a clinical trial of selective ER modulators (SERMs) whose administration culminated in the prevention of further PC progression as a major clinical outcome in men [54], which had only been shown in vivo through the antagonism of ERα, not ERβ [55]. Here, ESR1 is linked to pachyonychia congenita.